
The agreement will improve access to twice-yearly Lenacapavir across Latin America and the Caribbean

The centre in California supports the company’s $32bn US investment

Over 240 million people worldwide live with chronic hepatitis B

The new three-year agreement builds on an existing two-year relationship

PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide

RSV affects approximately 64 million people around the world each year

Symptoms of COPD include breathlessness, persistent cough and frequent chest infections

Approval supported by positive results from phase 3 trial

The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales

An estimated 1.2 million people in the US are currently living with the virus

The deal includes a PDE3/4 inhibitor in clinical development for COPD

More than 50,000 cases of the blood cancer are diagnosed in Europe each year